Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC):...

Area of Science:

• Oncology
• Biochemistry
• Clinical Trials

Background:

• Circulating bone metabolism biomarkers correlate with overall survival (OS) in advanced prostate cancer.
• Previous SWOG S1216 trial data indicated elevated bone biomarkers increase mortality risk in hormone-sensitive prostate cancer (HSPC).
• This analysis focuses on the association between bone biomarkers and OS in HSPC patients with documented bone metastases.

Purpose of the Study:

• To investigate the prognostic value of bone biomarkers for overall survival (OS) in men with bone metastatic hormone-sensitive prostate cancer (HSPC).
• To identify patient subgroups with differential OS outcomes based on bone biomarker levels.
• To validate findings from previous analyses within a specific subset of the SWOG S1216 trial.

Main Methods:

• Assessed bone resorption markers (C-telopeptide [CTx], Pyridinoline [PYD]) and bone formation markers (C-terminal collagen propeptide [CICP], bone alkaline phosphatase [BAP]) in blood samples.
• Utilized recursive partitioning in a training set to define cut-points for biomarkers and prognostic groups.
• Employed Cox proportional hazards models in a validation set to evaluate biomarker impact on OS, adjusting for clinical variables.

Main Results:

• Elevated CICP, CTX, and PYD levels were strongly prognostic for OS in men with bone metastatic HSPC.
• Hazard ratios indicated significant associations between elevated CICP, CTX, and PYD and worse OS.
• Prognostic models identified four patient groups with distinct median OS, ranging from 2.3 to 7.5 years, based on bone biomarker levels.

Conclusions:

• Elevated serum bone metabolism markers are significantly associated with poorer OS in men with HSPC and bone metastases.
• Bone biomarker levels, individually and combined with clinical factors, effectively stratify patients into unique prognostic subsets.
• These findings support the use of bone biomarkers for risk stratification and personalized management in bone metastatic HSPC.